Outcomes of Hypofractional Tomotherapy in Patients with Stage III Nonsmall Cell Lung Cancer Who Are Not Eligible for Surgery or Concurrent Chemoradiation

Abstract EN

Purpose.

We assessed the clinical outcomes and toxicities following hypofractionation with helical tomographic intensity-modulated radiotherapy technology (tomotherapy) in patients with stage III non-small cell lung cancer (NSCLC) who were not candidates for surgery or concurrent chemoradiation.

Methods.

Forty-three patients with stage III NSCLC who were treated between 2011 and 2017 were enrolled.

The prescription doses for gross target volume and clinical target volume were 70 Gy and 60 Gy (respectively) delivered in 15–25 fractions over 3–5 weeks.

Results.

The median overall survival (OS) time was 34.23 (range 11.33–99.33) months.

The estimated 1-, 2-, and 3-year OS rates were 97.7%, 74.4%, and 55.9%, respectively; the corresponding progression-free survival (PFS) rates were 79.1%, 53.5%, and 36.1%, respectively.

The local disease recurrence, regional disease recurrence, and distant metastasis rates at 3 years were 4.7%, 11.62%, and 55.81%, respectively.

On multivariate analysis, dose regimen (<19 f vs.

≥19 f) was an independent prognostic factor affecting OS, PFS, and DM (p<0.05).

Seven patients developed grade 1-2 acute radiation pneumonia (RP), 5 patients developed grade 1-2 late RP, while 3 patients developed grade 3 late RP.

None of the patients developed grade 4-5 radiation lung injury.

Conclusion.

Tomotherapy may be an effective treatment option for patients with stage III NSCLC.

It may be a viable alternative to surgery with lower incidence of side effects.